(Q38658737)

5 September 2017

title

A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone (English)

1 reference

5 September 2017

0 references

1

Jorge E Osorio

1 reference

5 September 2017

Derek Wallace

2

1 reference

5 September 2017

Dan T Stinchcomb

series ordinal

3

1 reference

5 September 2017

publication date

4 December 2015

1 reference

Expert Review of Vaccines

5 September 2017

published in

1 reference

5 September 2017

volume

15

1 reference

5 September 2017

issue

4

1 reference

5 September 2017

page(s)

497-508

1 reference

The global distribution and burden of dengue

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Human immune responses to dengue virus infection: lessons learned from prospective cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Serotype-Specific Differences in the Risk of Dengue Hemorrhagic Fever: An Analysis of Data Collected in Bangkok, Thailand from 1994 to 2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Epidemiology of dengue disease in the Philippines (2000-2011): a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Epidemiological trends of dengue disease in Thailand (2000-2011): a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Epidemiological trends of dengue disease in Brazil (2000-2010): a systematic literature search and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Epidemiological trends of dengue disease in Mexico (2000-2011): a systematic literature search and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Epidemiology of dengue disease in Malaysia (2000-2012): a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Recent epidemiological trends of dengue in the French territories of the Americas (2000-2012): a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Lineage II of Southeast Asian/American DENV-2 is associated with a severe dengue outbreak in the Peruvian Amazon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Emergence of the Asian 1 genotype of dengue virus serotype 2 in viet nam: in vivo fitness advantage and lineage replacement in South-East Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Increased replicative fitness of a dengue virus 2 clade in native mosquitoes: potential contribution to a clade replacement event in Nicaragua

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Neutralizing antibodies after infection with dengue 1 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Antibody to dengue 1 detected more than 60 years after infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Replication of the primary dog kidney-53 dengue 2 virus vaccine candidate in Aedes aegypti is modulated by a mutation in the 5' untranslated region and amino acid substitutions in nonstructural proteins 1 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Dengue: a continuing global threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

T-cell immunity to infection with dengue virus in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Efficacy of a tetravalent dengue vaccine in children in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Identifying protective dengue vaccines: guide to mastering an empirical process

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

The dengue vaccine pipeline: Implications for the future of dengue control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Controlling dengue with vaccines in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Potential opportunities and perils of imperfect dengue vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Evaluation of dengue virus strains for human challenge studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1128328

10.1586/14760584.2016.1128328

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference